Literature DB >> 19440166

Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis.

Charles H Crawford1, Leah Y Carreon, Mark D McGinnis, Mitchell J Campbell, Steven D Glassman.   

Abstract

STUDY
DESIGN: Retrospective evaluation of perioperative complications with recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge (rhBMP-2/ACS) versus iliac crest bone graft (ICBG) for instrumented posterior cervical fusion.
OBJECTIVE: To determine the risk of perioperative complications using rhBMP-2/ACS for posterior cervical fusion compared with ICBG. SUMMARY OF BACKGROUND DATA: There is substantial use of rhBMP-2/ACS as a bone graft substitute for spine fusions outside the Food and Drug Administration-approved indication of anterior lumbar interbody fusion. Efficacy for inducing fusion and avoidance of iliac crest donor-site complications are frequent reasons cited for its use. Previous studies have reported use in the anterior lumbar spine, the posterior lumbar spine, and in the anterior cervical spine. Site-specific perioperative complications that have been reported, especially with use in the anterior cervical spine, confirm that safety and efficacy should be established for specific anatomic sites and clinical indications.
METHODS: From July 2002 to February 2005, a consecutive series of patients who underwent instrumented posterior cervical fusion were identified. Patients received either rhBMP-2/ACS or ICBG based on the discretion of the surgeon. Patients were excluded if they had a preoperative diagnosis of trauma, tumor, or infection, or if they underwent a concomitant anterior procedure. Seventy-seven patients met the inclusion criteria. Forty-one of these patients received rhBMP-2/ACS and 36 received ICBG. Standard demographic, surgical, and perioperative complication data were collected from the medical records.
RESULTS: There were no significant differences in age, gender distribution, smoking status, number of surgical levels, blood loss, operative time, or length of stay between the 2 groups. There were more posterior cervical wound complications requiring treatment in the rhBMP- 2/ACS group (6, 14.6%) versus the ICBG group (1, 2.8%), although this was not statistically significant (P = 0.113). One patient (2.8%) in the ICBG group had a wound complication at the iliac crest donor site. Additional perioperative complications were noted in 3 patients (7.3%) in the ICBG group and none in the rhBMP-2/ACS group.
CONCLUSION: The higher incidence of posterior cervical wound complications in the rhBMP-2/ACS group, although not statistically significant, may be related to an inflammatory response to rhBMP-2. This potential risk must be weighed against the elimination of donor-site complications associated with ICBG harvesting, and considered in light of ultimate clinical outcome. Additional studies are needed to clarify this issue, as well as to determine optimal dosing and carrier for usage in the posterior cervical spine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19440166     DOI: 10.1097/BRS.0b013e3181a2da08

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  19 in total

1.  BMP-2 and TGF-β3 do not prevent spontaneous degeneration in rabbit disc explants but induce ossification of the annulus fibrosus.

Authors:  Daniel Haschtmann; Stephen J Ferguson; Jivko V Stoyanov
Journal:  Eur Spine J       Date:  2012-05-26       Impact factor: 3.134

Review 2.  Cervical laminectomy and instrumented lateral mass fusion: techniques, pearls and pitfalls.

Authors:  Michael Mayer; Oliver Meier; Alexander Auffarth; Heiko Koller
Journal:  Eur Spine J       Date:  2013-05-29       Impact factor: 3.134

3.  Cyst-Like Osteolytic Formations in Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) Augmented Sheep Spinal Fusion.

Authors:  Hsin Chuan Pan; Soonchul Lee; Kang Ting; Jia Shen; Chenchao Wang; Alan Nguyen; Emily A Berthiaume; Janette N Zara; A Simon Turner; Howard B Seim; Jin Hee Kwak; Xinli Zhang; Chia Soo
Journal:  Am J Pathol       Date:  2017-05-11       Impact factor: 4.307

4.  "Same day" ex-vivo regional gene therapy: a novel strategy to enhance bone repair.

Authors:  Mandeep S Virk; Osamu Sugiyama; Sang H Park; Sanjiv S Gambhir; Douglas J Adams; Hicham Drissi; Jay R Lieberman
Journal:  Mol Ther       Date:  2011-02-22       Impact factor: 11.454

5.  Bone morphogenetic protein in complex cervical spine surgery: A safe biologic adjunct?

Authors:  Darren R Lebl
Journal:  World J Orthop       Date:  2013-04-18

6.  Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model.

Authors:  Mandeep S Virk; Farhang Alaee; Hezhen Tang; Michael S Ominsky; Hua Zhu Ke; Jay R Lieberman
Journal:  J Bone Joint Surg Am       Date:  2013-04-17       Impact factor: 5.284

7.  A consensus statement regarding the utilization of BMP in spine surgery.

Authors:  Brett Walker; John Koerner; Sriram Sankarayanaryanan; Kris Radcliff
Journal:  Curr Rev Musculoskelet Med       Date:  2014-09

8.  Use of recombinant human bone morphogenetic protein-2 as an adjunct for instrumented posterior arthrodesis in the occipital cervical region: An analysis of safety, efficacy, and dosing.

Authors:  D Kojo Hamilton; Justin S Smith; Davis L Reames; Brian J Williams; Christopher I Shaffrey
Journal:  J Craniovertebr Junction Spine       Date:  2010-07

9.  Costs and frequency of "off-label" use of INFUSE for spinal fusions at one institution in 2010.

Authors:  Nancy E Epstein; Garry S Schwall
Journal:  Surg Neurol Int       Date:  2011-08-17

10.  Growth factors produced by bone marrow stromal cells on nanoroughened titanium-aluminum-vanadium surfaces program distal MSCs into osteoblasts via BMP2 signaling.

Authors:  Michael B Berger; Kyla B Bosh; Thomas W Jacobs; D Joshua Cohen; Zvi Schwartz; Barbara D Boyan
Journal:  J Orthop Res       Date:  2020-10-12       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.